CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Lifestyle Modifications for Preventing and Treating Heart Failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)
|<<... 9 10 11 12 13 14 15 16 >>|

Clinical TrialNovember 10, 2018

JOURNAL：N Engl J Med. Article Link

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

SD Wiviott，I Raz，DECLARE–TIMI 58 Investigators. Keywords: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Hypertension, Smoking

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top